EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Opportunistic assessment of steatotic liver disease in lung cancer screening eligible individuals

Jakob Weiss iD, Simon Bernatz, Justin Johnson, Vamsi Thiriveedhi, Raymond H Mak, Andriy Fedorov, Michael T Lu, Hugo J W L Aerts

Journal of Internal Medicine · 2025

DOI: 10.1111/joim.20053 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Internal Medicine, 2025. Verfasst von Jakob Weiss und 7 weiteren Autor:innen. Beteiligte Einrichtung: Artificial Intelligence in Medicine (AIM) Program, Mass General Brigham, Harvard Medical School, Harvard Institutes of Medicine (HIM), Boston, Massac…. Hauptthemen laut MEDLINE: Lung Neoplasms, Early Detection of Cancer, Fatty Liver. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, Deutsche Forschungsgemeinschaft (DFG, German Research Foundation, European Union-European Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Steatotic liver disease (SLD) is a potentially reversible condition but often goes unnoticed with the risk for end‐stage liver disease.

Purpose

To opportunistically estimate SLD on lung screening chest computed tomography (CT) and investigate its prognostic value in heavy smokers participating in the National Lung Screening Trial (NLST). Material and methods We used a deep learning model to segment the liver on non‐contrast‐enhanced chest CT scans of 19,774 NLST participants (age 61.4 ± 5.0 years; 41.2% female) at baseline and on the 1‐year follow‐up scan if no cancer was detected. SLD was defined as hepatic fat fraction (HFF) ≥5% derived from Hounsfield unit measures of the segmented liver. Participants with SLD were categorized as lean (body mass index [BMI] < 25 kg/m 2 ) and overweight (BMI ≥ 25 kg/m 2 ). The primary outcome was all‐cause mortality. Cox proportional hazard regression assessed the association between (1) SLD and mortality at baseline and (2) the association between a change in HFF and mortality within 1 year.

Results

There were 5.1% (1000/19,760) all‐cause deaths over a median follow‐up of 6 (range, 0.8–6) years. At baseline, SLD was associated with increased mortality in lean but not in overweight/obese participants as compared to participants without SLD (hazard ratio [HR] adjusted for risk factors: 1.93 [95% confidence interval 1.52–2.45]; p = 0.001). Individuals with an increase in HFF within 1 year had a significantly worse outcome than participants with stable HFF (HR adjusted for risk factors: 1.29 [1.01–1.65]; p = 0.04).

Conclusion

SLD is an independent predictor for long‐term mortality in heavy smokers beyond known clinical risk factors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsEarly Detection of CancerFatty LiverHumansFemaleMiddle AgedMaleTomography, X-Ray ComputedAgedRisk FactorsDeep Learning

Stichwörter der Autor:innen

CT imagingartificial intelligencelung cancer screeningopportunisticrisk assessmentsteatotic liver disease

Autor:innen und Institutionen

  • Artificial Intelligence in Medicine (AIM) Program, Mass General Brigham, Harvard Medical School, Harvard Institutes of Medicine (HIM), Boston, Massachusetts, USA.
  • Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Radiology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Diagnostic and Interventional Radiology, Faculty of Medicine, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany.
  • Radiology and Nuclear Medicine, CARIM & GROW, Maastricht University, Maastricht, The Netherlands.
  • Cardiovascular Imaging Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.

ORCID-Profile: Jakob Weiss

Förderung

  • NIH HHS
  • Deutsche Forschungsgemeinschaft (DFG, German Research Foundation
  • European Union-European Research Council
  • NCI NIH HHS
  • National Institutes of Health

Zitieren

APA

Weiss, J., Bernatz, S., Johnson, J., Thiriveedhi, V., Mak, R. H., Fedorov, A., Lu, M. T., & Aerts, H. J. W. L. (2025). Opportunistic assessment of steatotic liver disease in lung cancer screening eligible individuals. Journal of Internal Medicine. https://doi.org/10.1111/joim.20053

Vancouver

Weiss J, Bernatz S, Johnson J, Thiriveedhi V, Mak RH, Fedorov A, et al. Opportunistic assessment of steatotic liver disease in lung cancer screening eligible individuals. Journal of Internal Medicine. 2025. doi:10.1111/joim.20053

BibTeX
@article{Weiss2025,
  author = {Weiss, Jakob and Bernatz, Simon and Johnson, Justin and Thiriveedhi, Vamsi and Mak, Raymond H and Fedorov, Andriy and Lu, Michael T and Aerts, Hugo J W L},
  title = {Opportunistic assessment of steatotic liver disease in lung cancer screening eligible individuals},
  journal = {Journal of Internal Medicine},
  year = {2025},
  doi = {10.1111/joim.20053}
}
Kostenlos starten →